Background
==========

The statins, by inhibiting HMG-CoA reductase activity, reduce cholesterol and isoprenoid synthesis \[[@B1]\]. They are being used primarily in the prevention of atherosclerosis \[[@B2],[@B3]\]. They have proven to be beneficial in preventing stroke \[[@B4]\] and may increase bone formation \[[@B5]\] and lower the risk of dementia \[[@B6]\]. Some of the benefits in patients with myocardial infarction are independent of cholesterol levels. Statins also inhibit cellular proliferation and induce apoptosis of tumor cells \[[@B7]\]. Essential fatty acids have several properties similar to the statins \[[@B8],[@B9]\] and Das \[[@B10]\] has suggested that \"essential fatty acids and their metabolites may serve as second messengers of the actions of statins.\"

Statins affect prostaglandin (PG) production. Mevastatin or lovastatin, at 25 μM, induce PGI~2~production and cyclooxygenase (COX)-2 in human aorta smooth muscle cells \[[@B11]\]. Mevalonate and geranylgeranyl-pyrophosphate block these stimulations implicating the cholesterol biosynthetic pathway in this up-regulation. However, fluvastatin down-regulates rather than up-regulates COX-2 expression in human umbilical vein endothelial cells \[[@B12]\] and lovastatin reduces PGI~2~production in bovine endothelial cells, human skin fibroblasts and arterial smooth muscle cells \[[@B13]\].

I observed that in rat liver cells, the statins stimulate the release of an essential fatty acid, arachidonic acid (AA) and stimulate production of its metabolite, PGI~2~. These stimulations are independent of HMG-CoA reductase activity as measured by the lack of any suppression by mevalonate.

Results
=======

The release of AA from rat liver cells after 6 h incubation with mevastatin, lovastatin and simvastatin is shown in Fig. [1](#F1){ref-type="fig"}. An extract of the pharmaceutical product Lipitor^®^also significantly stimulates AA release (data not shown). The release of AA as a function of time in the presence of 50 μM lovastatin or simvastatin is shown in Fig. [2](#F2){ref-type="fig"}. Stimulation by lovastatin and simvastatin is observed after as little as 15 min incubation with cells (the time of release with mevastatin was not studied). Preincubation of the cells for 2 h with 1 μM actinomycin did not alter the quantity of AA release stimulated by 6 h incubation with simvastatin \[17.0 ± 0.30 % (5) was released in the absence of actinomycin compared to 17.6 ± 0.60 % (5) released in its presence\]. These results indicate that transcription is not required. I have shown previously that under these conditions, induced PG production is inhibited \[[@B14],[@B15]\]. Nor does mevalonate, the direct product of HMG-CoA reductase, affect the stimulated release by 50 μM simvastatin (Fig. [3](#F3){ref-type="fig"}).

![AA release by mevastatin, lovastatin and simvastatin. Cells were incubated with these statins at the concentrations shown for 6 h. The analyses were performed on triplicate culture dishes. \* Statistically significant *vs*MEM/BSA control (*P*\< 0.05). Data are representative of several independent experiments.](1476-511X-2-1-1){#F1}

![Time course of release of AA after incubation with 50 μM lovastatin (○), 50 μM simvastatin (△) and the MEM/BSA controls (□). Analyses were performed on triplicate or duplicate dishes. The average value is recorded.](1476-511X-2-1-2){#F2}

![Effect of 188 μM mevalonate on AA release from rat liver cells incubated 6 h in the presence of 50 μM simvastatin. The analyses were performed on triplicate dishes. The bars show the mean values and brackets the SEM. This experiment was repeated two times with similar results.](1476-511X-2-1-3){#F3}

PGI~2~production is enhanced in cells incubated with lactacystin in the presence of TPA (Fig. [4](#F4){ref-type="fig"}). Simvastatin, mevastatin and lovastatin enhance the induced PGI~2~levels (Fig. [4](#F4){ref-type="fig"}). Even at 70 min the quantity of PGI~2~produced by lactacystin plus TPA increased in the presence of 30 μM simvastatin (Fig. [5](#F5){ref-type="fig"}). The effect of 96 μM mevalonate on simvastatin\'s amplification of induced PGI~2~in the presence of lactacystin plus TPA is shown in Fig. [6](#F6){ref-type="fig"}. Mevalonate does not suppress the stimulated PGI~2~production. Mevalonate amplifies even further the effect of simvastatin on lactacystin plus TPA induced PGI~2~production, suggesting a role for a downstream isoprenoid in the induction pathway (Fig. [6](#F6){ref-type="fig"}).

![Effect of 27 μM simvastatin, 100 μM mevastatin and 50 μM lovastatin on lactacystin plus TPA induced 6-keto-PGF~1α~production after 6 h incubation. At the levels tested, simvastatin, mevastatin and lovastatin alone do significantly stimulate basal PGI~2~production, but by \< 1 ng/ml. The analyses were performed on triplicate dishes. \* Statistically significant *vs*lactacystin plus TPA (*P*\< 0.05). This experiment was repeated with similar results.](1476-511X-2-1-4){#F4}

![Time course of 6-keto-PGF~1α~production during incubation with MEM/BSA (□), 30 μM simvastatin (△), lactacystin plus TPA (○) and lactacystin plus TPA plus 30 μM simvastatin (\*). Analyses were performed on triplicate or duplicate dishes. The average value is recorded.](1476-511X-2-1-5){#F5}

![Effect of 96 μM mevalonate on 6-keto-PGF~1α~produced by stimulation with 30 μM simvastatin in the presence of lactacystin plus TPA after a 6 h incubation. Analyses were performed on triplicate dishes. \* Statistically significant *vs*lactacystin plus TPA (*P*\< 0.05) \*\* Statistically significant *vs*lactacystin plus TPA and simvastatin (*P*\< 0.05).](1476-511X-2-1-6){#F6}

Discussion
==========

Mevastatin, lovastatin, simvastatin and atorvastatin stimulate the release of AA from rat liver cells. They do so even after preincubation with actinomycin. Mevalonate, the product of HMG-CoA reductase, does not suppress simvastatin\'s stimulated AA release. Therefore, it appears that neither transcription nor cholesterol biosynthesis is required for this stimulated AA release. HMG-CoA reductase activity also is not required for up-regulation of induced PGI~2~production by simvastatin.

AA has a number of important bioactivities. It serves as substrate for cyclooxygenases, lipoxygenases and cytochrome P450 epoxygenases. After additional enzyme reactions the products yield a variety of biologically active prostanoids \[[@B16]\]. AA also activates leukocyte NADPH oxidase \[[@B17]\], activates PPAR receptors \[[@B18]\], affects H^+^channel \[[@B19]\], K^+^channel \[[@B20]\] and Ca ^2+^channel activities \[[@B21]\]. It elevates heat shock gene expression \[[@B22]\], induces apoptosis \[[@B23]\] and inhibits Ca ^2+^induced Ca ^2+^release \[[@B24]\]. In human embryonic kidney cells it down-regulates sterol regulatory element-binding proteins (SREBPs), especially the SREBP-1a isoform \[[@B25]\]. The release of AA after incubation with sulindac and the stimulation of apoptosis *via*conversion of sphingomyelin to ceramide \[[@B26]\] is a mechanism proposed to mediate cancer chemoprevention by nonsteroidal anti-inflammatory drugs \[[@B26]\]. I have postulated that, in addition to nonsteroidal anti-inflammatory drugs, the continuous use of other commonly prescribed drugs that release AA is potentially cancer preventative \[[@B27]\].

The major product of PGH~2~metabolism by these rat liver cells is PGI~2~, although 10% or less of the metabolites are PGE~2~and PGF~2α~\[[@B28]\]. In this study, only PGI~2~was measured. Although PGI~2~synthase is an induced enzyme \[[@B29]\], the increased PGI~2~production probably reflects COX activity \[[@B27]\]. Up-regulation of PGI~2~production is in agreement with the findings of Degreave et al \[[@B11]\] who showed that mevastatin and lovastatin up-regulate COX activity in human aortic smooth muscle cells. However, while up-regulation in the muscle cell system involves cholesterol biosynthesis, the up-regulation observed in rat liver cells does not. Statins also have been shown to down-regulate COX activity in human umbilical vein endothelial cells \[[@B12]\]. In addition to differences inherent in the type of cells being studied by the various investigators, the apparently contradictory findings may also be due to examination of the cells at different stages of growth. The published studies \[[@B11]-[@B13]\] use cells at confluent densities and also may have been in the G~0~stage of growth. The rat liver cells studied in this report were at low density (dividing cells).

Since statins activate at μM concentrations, it is likely that the release of AA and effects on PGI~2~production are reflections of interaction with cell membranes.

Conclusions
===========

Statins stimulate AA release from and PGI~2~production in rat liver cells. It is not yet possible to assign a biological consequence to either stimulation. However, in view of the many biological activities of AA, its release could generate the essential fatty acid that is postulated to be a mediator of statin action \[[@B10]\]. Such mediation does not involve cholesterol biosynthesis.

Materials
=========

The C-9 rat liver cell line was purchased from the American Type Culture Collection (Manassa, VA, USA). The cells were maintained in Eagle\'s minimum essential medium (MEM) supplemented with 10% fetal bovine serum. The \[^3^H\] AA (91.8 Ci/mmol) was from NEN Life Science Products, Inc., (Boston, MA, USA). Mevastatin, lovastatin, DL-mevalonic acid lactone were from Sigma Chemical Co. (St. Louis, MO, USA). I thank Dr. Gregory R. Mundy, Institute for Drug Development, San Antonio, TX, for the generous supply of simvastatin. For the experiments with atorvastatin, CH~3~CH~2~OH and CH~3~OH extracts of Lipitor^®^tablets were used.

Methods
=======

On the day prior to experiments, the rat liver cells were treated with 0.25% trypsin-EDTA and, after addition of minimal essential media (MEM) containing 10% fetal calf serum, the floating cells were seeded onto 35 mm culture dishes. The plating densities varied from 0.1 to 0.5 × 10^5^cells/35 mm dish. The freshly seeded cultures were incubated 24 h to allow for cell attachment. After decantation of MEM containing the fetal bovine serum, 1.0 ml fresh MEM containing 10% fetal bovine serum and \[^3^H\] AA (0.2 μCi/ml) was added and the cells incubated for another 24 h. The cells were washed 4 times with MEM and incubated for various periods of time with 1.0 ml of different concentrations of each compound in MEM containing 1.0 mg BSA/ml. The culture fluids were then decanted, centrifuged at 2000 × g for 10 min, and 200 μl of the supernate counted for radioactivity. Radioactivity recovered in the washes before the 6 h incubation was compared to input radioactivity to calculate the % radioactivity incorporated into the cells \[[@B30]\].

For PGI~2~production, 1.0 ml of MEM supplemented with 10% fetal bovine serum, void of \[^3^H\] AA, was added after the first 24 h incubation. The cells were incubated for another 24 h, washed three times with MEM, then incubated with lactacystin plus TPA and the compounds in MEM containing BSA for various periods of time. The culture fluids were decanted and analyzed for 6-keto-PGF~1α~, the stable hydrolytic product of PGI~2~, by radioimmunoassay \[[@B31]\].

Presentation of data
====================

The \[^3^H\] AA release is presented as a percentage of the radioactivity incorporated by the cells. Three to six culture dishes were used for each experimental point. The data are expressed as mean values ± SEM (number of dishes). The data were statistically evaluated by unpaired *Student\'s t-test*. A *P*value \< 0.05 was considered significant.
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